Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Chubb
Mallinckrodt
Chinese Patent Office
Merck
AstraZeneca
Colorcon
Citi
Cantor Fitzgerald
Daiichi Sankyo

Generated: August 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Parallel selex
Abstract:This invention discloses a method for coevolving products from two or more reactants, along with the nucleic acid that can facilitate the reaction for making the products. The invention further discloses the products and facilitating nucleic acids produced by said method.
Inventor(s): Eaton; Bruce E. (Boulder, CO), Gold; Larry (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Jun 05, 1995
Application Number:08/462,389
Claims:1. A non-naturally occurring facilitating nucleic acid that facilitates a bond formation reaction between a first reactant and a free reactant, wherein said bond formation reaction is selected from the group consisting of a condensation reaction, a hydrolysis reaction, a cycloaddition reaction, a conjugate addition reaction, an aldol condensation reaction, a cyclopropanation reaction, a hydrogenation reaction, and a cyclotrimerization reaction, wherein each reactant is comprised of a small organic molecule with a molecular weight in the range of 2 to 1000, and further wherein said first reactant is coupled to said nucleic acid.

2. A non-naturally occurring facilitating nucleic acid which increases the reaction rate of a bond formation reaction to form a product from a first reactant and a free reactant, wherein said bond formation reaction is selected from the group consisting of a condensation reaction, a hydrolysis reaction, a cycloaddition reaction, a conjugate addition reaction an aldol condensation reaction, a cyclopropanation reaction, a hydrogenation reaction, and a cyclotrimerization reaction, wherein each reactant is comprised of a small organic molecule with a molecular weight in the range of 2 to 1000, and further wherein said first reactant is coupled to said nucleic acid.

3. The facilitating nucleic acid of claim 1 wherein the nucleic acid is selected from the group consisting of single-stranded RNA, single-stranded DNA, and double-stranded DNA.

4. The non-naturally nucleic acid of claim 1 wherein the nucleic acid is selected from the group consisting of single-stranded RNA, single-stranded DNA, and double-stranded DNA.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
AstraZeneca
Teva
Chubb
US Army
Covington
Cantor Fitzgerald
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot